Biotech & Pharmaceuticals
BioPharm Insight is the ideal solution to conduct due diligence to make informed decisions on corporate strategies, benchmark terms of deals and gain competitive intelligence. Subscribers have access to our robust database of drugs, companies, licensing deals, M&A activity, financing deals and more. This data is essential for accurately benchmarking potential deals. In addition, our team of investigative journalists publish real-time breaking news as well as predictive and competitive intelligence 3-12 months ahead of industry catalysts.
Licensing and M&A Deals
We have the largest database of drug licensing deals in the industry and cover many different deal types including co-development, promotional and intellectual property. All deals have a disclosed licensor, licensee, drug information and a snapshot of the company at the time of the deal. Our M&A data comes from our sister company, Mergermarket, which is the industry leader in M&A deal data. We take this data and integrate it with our drug database so you’re able to find deals where the target company’s pipeline was focused on certain types of drugs. This information enables you to benchmark potential deals and discover new partnership opportunities.
Our team of investigative journalists and editorial analysts build and manage relationships with medical experts and key opinion leaders to deliver news articles focused on future events such as:
- Expected Clinical Trial Results
- Potential Mergers and Acquisitions
- Licensing and Partnership Opportunities
- Future Financing Deals and IPOs
- Regulatory and Reimbursement Trends
BioPharm Insight has over 300 indication profiles which provide all relevant information including proprietary disease descriptions, analytics on active pipelines, key players in the market, epidemiology data and sales forecasts. These summaries are an essential resource to stay informed and expand your reach into any new areas.